|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1993-7-30
|
|
pubmed:abstractText |
One hundred large bowel carcinomas operated on between 1978 and 1982 were studied immunohistochemically with regard to expression of HLA-DR antigens. Three sections from each tumour were investigated by a semiquantitative scoring system, and a mean score for each patient established. Based on this scoring system, the tumours were divided into three groups: 0; 0.1-1.0; and > 1.0. All patients were followed until death (n = 68) or until June 1, 1992, and all cancer-specific deaths (n = 56) have been recorded. Analysis of survival in the whole patient group showed significant difference between the three levels of tumour HLA-DR expression (P = 0.006); patients who had tumours with strong HLA-DR expression showing the best survival. In a stratified analysis after Dukes' stages there was still a significant difference (P > 0.001) between the three levels of HLA-DR staining intensity. After a multiple regression analysis (Cox) with correction for different variables, the HLA-DR expression maintained its significance as a risk factor. To our knowledge this is the first time a relationship between intensity of tumour DR expression and survival has been shown in large bowel carcinoma.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-13596482,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1475624,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1566080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1712347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1732421,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1901830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1912518,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-1913477,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-2350918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-2428757,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-2446645,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-2679456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-2856203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3125670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3143150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3146901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3192729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3426928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3529358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3721406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-3928856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-4035298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-4604796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6039601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6210275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6337854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6350234,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6354239,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6591602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-683276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6953153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-6954308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-7022096,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-74085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-843571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8318425-959840
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
80-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8318425-Adult,
pubmed-meshheading:8318425-Aged,
pubmed-meshheading:8318425-Aged, 80 and over,
pubmed-meshheading:8318425-Aneuploidy,
pubmed-meshheading:8318425-Carcinoembryonic Antigen,
pubmed-meshheading:8318425-Colonic Neoplasms,
pubmed-meshheading:8318425-Diploidy,
pubmed-meshheading:8318425-Female,
pubmed-meshheading:8318425-HLA-DR Antigens,
pubmed-meshheading:8318425-Humans,
pubmed-meshheading:8318425-Male,
pubmed-meshheading:8318425-Middle Aged,
pubmed-meshheading:8318425-Neoplasm Staging,
pubmed-meshheading:8318425-Prognosis,
pubmed-meshheading:8318425-Rectal Neoplasms,
pubmed-meshheading:8318425-Retrospective Studies,
pubmed-meshheading:8318425-Survival Analysis,
pubmed-meshheading:8318425-Time Factors
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis.
|
|
pubmed:affiliation |
Institute of Forensic Medicine, National Hospital, University of Oslo, Norway.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
